Psychedelics Briefs: Revitalist, Alchemy Wellness, Diamond Therapeutics, Awakn Life Sciences

Revitalist Lifestyle and Wellness announced this week that it has entered into a definitive agreement to acquire Alchemy Wellness, a ketamine clinic in Richmond, Virginia. With its acquisition, the latest step in an expansion plan that was launched in February 2021, Revitalist’s portfolio now includes 10 ketamine infusion clinics across 7 states.

The Richmond facility was founded in 2019 and is managed by Dr Randy Frederick, an emergency medicine physician and US Navy veteran who will continue to lead the facility. The clinic provides ketamine infusion treatments for mood disorders, such as depression, postpartum depression, bipolar depression, post-traumatic stress disorder, obsessive-compulsive disorder, and anxiety, as well as chronic pain syndromes.

Diamond Therapeutics Completes Last Patient Visit in Low-Dose Psilocybin Study

Diamond Therapeutics, a drug development company studying the use of non-psychedelic doses of psilocybin to treat mental health conditions, announced this week that it has completed the last patient visit in a Phase I clinical trial this month.

The trial is the first systematic, placebo-controlled, single ascending dose study to investigate the safety and tolerability of very low doses of psilocybin in humans. The study included 56 participants in 7 separate cohorts over 4 ½ months. Safety data was reviewed by 5 senior physicians. The trial was conducted in Toronto and supervised by Dr Isabella Szeto of BioPharma Services.

Diamond Therapeutics expects to have topline results available in May with a more complete analysis to follow.

Awakn Clinic in London Receives CQC Approval

Awakn Life Sciences, a biotech firm developing psychedelic therapeutics to treat addiction, announced recently that Awakn Clinics London has received the Care Quality Commission’s (CQC) approval to begin treatments for addiction and mental health disorders.

The London location is 1 of 3 Awakn clinics in Europe, along with facilities in Bristol, United Kingdom, and Oslo, Norway. The 3 clinics offer ketamine-assisted therapy to treat addiction and mental health disorders. Having received the CQC approval, the London clinic will receive a schedule 2 license that allows the facility to administer ketamine.

References

Revitalist increases clinic count to 10 with the acquisition of a Virginia ketamine clinic. News release. Revitalist Lifestyle and Wellness. March 29, 2022. Accessed March 30, 2022.

Diamond Therapeutics achieves last patient last visit in clinical trial of low-dose psilocybin. News release. Diamond Therapeutics. March 29, 2022. Accessed March 30, 2022.

Awakn Life Sciences receives regulatory approval for flagship clinic in London to begin delivering treatments. News release. March 17, 2022. Accessed March 30, 2022.